THE EFFICACY OF DUVELISIB MONOTHERAPY FOLLOWING DISEASE PROGRESSION ON OFATUMUMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL OR SLL IN A PHASE 3 CROSSOVER EXTENSION STUDY

European Haematology Association

Abstract: PF354

Type: Poster Presentation

Presentation during EHA23: On Friday, June 15, 2018 from 17:30 - 19:00

Location: Poster area

Background
Duvelisib, an oral dual inhibitor of PI3K-δ, γ, is being developed for the treatment of hematologic malignancies, including relapsed/refractory (RR) CLL/SLL. In the Phase 3 DUO study (NCT02004522) duvelisib monotherapy demonstrated significant improvement compared to ofatumumab monotherapy (PFS 13.3 vs 9.9 mo. p<0.0001; ORR 74% vs 45% p <0.0001) with a manageable safety profile (Flinn, ASH 2017). Study IPI-145-12 (NCT02049515) is an open-label, optional, crossover extension study where pts with confirmed progressive disease (PD) on DUO were given the option to receive the opposite treatment. 

 

Read Abstract